The role of the E3 ubiquitin ligase murine double minute 2 (Mdm2) in regulating the stability of the p53 tumor suppressor is well documented. By contrast, relatively little is known about p53-independent activities of Mdm2 and the role of Mdm2 in cellular differentiation. Here we report a novel role for Mdm2 in the initiation of adipocyte differentiation that is independent of its ability to regulate p53. We show that Mdm2 is required for cAMP-mediated induction of CCAAT/enhancer-binding protein d (C/EBPd) expression by facilitating recruitment of the cAMP regulatory element-binding protein (CREB) coactivator, CREB-regulated transcription coactivator (Crtc2)/TORC2, to the c/ebpd promoter. Our findings reveal an unexpected role for Mdm2 in the regulation of CREB-dependent transactivation during the initiation of adipogenesis. As Mdm2 is able to promote adipogenesis in the myoblast cell line C2C12, it is conceivable that Mdm2 acts as a switch in cell fate determination.
1
C/EBPb and C/EBPd are induced early and transiently during differentiation and are considered to play key roles during the initiation of the adipogenic program. The two C/EBPs act in concert with overlapping, but not identical, activities as indicated by the more severe adipose phenotype of mice lacking both C/EBPb and C/EBPd than that of mice lacking either of the two C/EBPs. 2 Activation of C/EBPb and C/EBPd leads to the induction of C/EBPa and PPARg expression orchestrating terminal adipocyte differentiation. 3 Besides PPARg and the three C/EBPs, other transcription factors are reported to be required for adipocyte differentiation. Activation of the cAMP regulatory element-binding protein (CREB) at the onset of adipocyte differentiation is critical for adipogenesis. [4] [5] [6] The recent cloning and characterization of a CREB cofactor family, denoted as CREB-regulated transcription coactivator (Crtc/TORC), have revealed how CREB can induce expression of distinct target genes dependent on different stimuli. [7] [8] [9] The murine double minute 2 (Mdm2) is an E3 ubiquitin ligase with oncogenic properties. Its importance in the control of p53 activity is underscored by the finding that knockout of p53 rescues the embryonic lethality of mice lacking mdm2. 10, 11 Deregulation of p53 activity in embryos lacking mdm2 leads to widespread apoptosis and ensuing embryonic death. 12 Although Mdm2 plays a critical role in the regulation of p53 signaling, an increasing body of evidence indicates that Mdm2 may exert p53-independent functions. 13 Amplification of the mdm2 gene occurs in 10% of all human cancers.
14 Interestingly, mdm2 is amplified in nearly all liposarcomas. 15 As the genetic aberration in a malignant transformation of an MSC was recently suggested to regulate the differentiation of the transformed cells, 16 the high prevalence of mdm2 amplification in liposarcomas could indicate an involvement of mdm2 in adipogenesis. Furthermore, the mdm2 gene is amplified in the widely used preadipocyte cell line, 3T3-L1. 17 Still, the functional consequence of its amplification and the role of Mdm2 in adipogenesis have not been elucidated. Here we show that Mdm2 regulates adipogenesis by promoting cAMP-mediated transcriptional activation of CREB and induction of C/EBPd expression by facilitating the recruitment of Crtc2 to a cAMP-response element (CRE) in the promoter of c/ebpd. Our unexpected findings identify Mdm2 as a novel critical player in the intricate network of factors that regulate CREBdependent transactivation and adipocyte differentiation.
Results
Mdm2 is required for adipogenesis ex vivo. The 3T3-L1 preadipocyte cell line and mouse embryonic fibroblasts (MEFs) have been instrumental for studying adipocyte differentiation. Although MEFs lacking Mdm2 cannot be established owing to the early embryonic lethality, 12 MEFs deficient for both p53 and Mdm2 can be obtained. 10, 11 When treating p53 À/À and p53 À/À ;mdm2 À/À MEFs with a standard hormonal cocktail (MDI) containing the cAMPelevating compound, 3-isobutyl-1-methylxanthine (IBMX), the glucocorticoid receptor agonist, dexamethasone (Dex) and insulin (Ins) commonly used for the induction of adipocyte differentiation, we observed a dramatic reduction in the adipogenic potential of p53 To establish a causal link between lack of Mdm2 and impaired adipogenesis, we attempted to rescue adipogenesis by restoring Mdm2 expression using retroviral transduction of p53
À/À MEFs. In accordance with a previous report, 18 cells expressing full-length Mdm2 did undergo cell cycle arrest (data not shown). This presumably relates to the use of the cDNA of mdm2 for retroviral expression, as overexpression of Mdm2 using a genomic clone harboring the entire mdm2 gene results in cell transformation. 19 To circumvent the cell cycle arrest imposed by expressing full-length mdm2 cDNA, we retrovirally expressed different portions of Mdm2 (Mdm2 aa 1-220 and Mdm2 aa 221-491) separately (Figures 1c and d) . P53 À/À ;mdm2 À/À MEFs expressing the N-terminal half of Mdm2 (Mdm2 aa 1-220) underwent adipocyte differentiation, whereas MEFs transduced with either empty vector or vector encoding Mdm2 aa 221-491 did not. Ectopic expression of full-length MdmX (or Mdm4), a protein that is structurally and functionally related to Mdm2, failed to restore adipogenesis in the p53 À/À ; mdm2 À/À MEFs (Supplementary Figure 1) . Collectively, these results indicate that Mdm2 regulates adipocyte differentiation, independent of its ubiquitin ligase activity and its ability to control p53 activity.
In an attempt to obtain evidence for the possible involvement of Mdm2 in adipogenesis in an in vivo setting, we used CT scanning to compare the amount of adipose tissue in mice harboring a missense mutation in p53 (p53 H/H ) 20 (Figure 2b ). This indicates that Mdm2 might act as a switch favoring adipogenesis over myogenesis.
Thayer and co-workers 21, 22 have previously shown that amplification of the mdm2 gene by microchromosomal transfer in the C2C12 myoblast cell line abrogates their ability to undergo myogenesis. We speculated if such C2C12 cells had increased propensity to undergo adipocyte differentiation. As expected, C2C12 cells in which mdm2 had been amplified (Rh18-11) had increased Mdm2 protein levels compared with both normal C2C12 and C2C12 cells subjected to microchromosomal transfer of DNA that did not harbor the mdm2 gene (Rh18-3) (Figure 2c ). Interestingly, when adipogenesis was induced in these three cell lines, only Rh18-11 cells accumulated fat as shown by Oil-Red-O staining and induced robust expression of adipocyte marker genes (Figures 2d  and e) . These data indicate that Mdm2 regulates cellular fate by promoting adipogenesis at the expense of myogenesis.
Mdm2 is required for the cAMP-mediated induction of C/EBPd. The inability of rosiglitazone to restore adipogenesis in MEFs lacking mdm2 indicated that induction of PPARg expression was perturbed in mdm2-null cells. Unlike in MEFs only lacking p53, neither PPARg1, PPARg2 nor C/EBPa mRNA levels were increased in p53 À/À ;mdm2 À/À MEFs in response to MDI and rosiglitazone treatment (Figure 3a) . However, retroviral-mediated restoration of PPARg2 expression was sufficient to overcome the block in adipocyte differentiation of p53 À/À ;mdm2 À/À MEFs (Supplementary Figure 2) . When we examined the expression pattern of C/EBPb and C/EBPd in p53 À/À and p53 À/À ;mdm2 À/À MEFs, we found that C/EBPb was induced to comparable levels in the two MEF genotypes, whereas C/EBPd induction was abrogated in p53
À/À MEFs ( Figure 3b ). Intriguingly, upregulation of an immediate-early-induced gene, Krox20, that is required for adipogenesis and for C/EBPb induction 23 was more robust in MEFs lacking mdm2 (Figure 3b ). Xanthine oxidoreductase (XOR) and Krü ppel-like factor 5 (KLF5) are induced transiently in a C/EBPb-and C/EBPd-dependent manner, respectively, during adipocyte differentiation. 24, 25 Consistent with the expression profiles of the two C/EBPs, XOR, but not KLF5, the expression was increased upon induction of differentiation in p53
À/À MEFs ( Figure 3b ). Taken together, these results indicate that Mdm2 is required for the induction of C/EBPd, but not C/EBPb during adipogenesis.
To examine whether the failure to induce C/EBPd expression is causally related to the impaired differentiation of p53 À/À ;mdm2 À/À MEFs, we transduced p53
MEFs with a retrovirus expressing C/EBPd. Forced expression of C/EBPd at least partially restored adipocyte differentiation (Supplementary Figure 3) .
As the expression of C/EBPd is increased shortly after induction of differentiation, its expression may be regulated by individual components of the hormonal cocktail. C/EBPd expression is normally considered to be induced by Dex both in preadipocytes and mature adipocytes. 26 C/EBPd expression is, however, also known to be regulated by cAMP during adipogenesis. 27 When treating wild-type MEFs with the individual components of the adipogenic cocktail, we observed an increase in C/EBPd expression upon treatment with Dex or IBMX alone, effects that were additive when both compounds were included ( Figure 3c ). Insulin or rosiglitazone did not affect C/EBPd expression. We observed the same We have recently shown that the adipogenic effect of elevated cAMP levels relies on the activation of both protein kinase A (PKA) and the exchange protein activated by cAMP (Epac). 28 Using selective activators of both PKA and Epac, we show that only the PKA activator augmented expression of C/EBPd ( Figure 3d ).
As p53
;mdm2 À/À failed to increase C/EBPd mRNA levels at the onset of adipogenesis, we speculated that this could be attributed to a failure to respond to either Dex or IBMX. As in wild-type MEFs, treating p53 À/À MEFs with Dex, IBMX or a combination led to an induction of C/EBPd expression. By contrast, treatment with Dex, but not IBMX, induced expression of C/EBPd in p53 Figure 4) . To ensure that the induction of C/EBPd was an early effect downstream of elevated cAMP levels, C/EBPd expression was measured 1 h after the addition of vehicle, IBMX or another cAMP-elevating compound, forskolin. In contrast to their effect in p53 À/À MEFs, addition of IBMX or forskolin to p53 À/À ; mdm2 À/À MEFs failed to increase C/EBPd mRNA levels ( Figure 3e) .
IBMX elevates the level of cAMP by inhibiting cAMPdegrading phosphodiesterases. The recent association of Mdm2 with phosphodiesterase degradation 29 raised the possibility that IBMX treatment resulted in different levels of cAMP in p53 À/À and p53
;mdm2 À/À MEFs. Contrary to this possibility, we found that MEFs of both genotypes had equal levels of cAMP both before and after IBMX stimulation (Supplementary Figure 5) . Collectively, these data suggest that Mdm2 is required for adipogenesis in a manner related to cAMP signaling.
Mdm2 is required for CREB activation. C/EBPd was recently suggested to be a putative CREB-regulated gene in a global screen for CREB target genes. 30 The canonical transcriptional pathway downstream of PKA activation is mediated by direct serine-133 phosphorylation of CREB. In addition to PKA, several other kinases can also activate CREB by phosphorylating serine 133. In fact, it is the mitogen-activated protein kinase (MAPK) that is responsible for CREB phosphorylation during the initiation of adipocyte differentiation. 28 An important function of PKA during adipose conversion is inhibition of the Rho kinase 28 that in turn can inhibit adipogenesis by blocking the MAPK-mediated phosphorylation of CREB. 31 To ensure that the failure to induce C/EBPd in the absence of Mdm2 was not a result of uncontrolled Rho-kinase activity, we concomitantly treated the p53 À/À ;mdm2 À/À MEFs with IBMX and increasing doses of a Rho-kinase inhibitor. The inhibitor failed to restore IBMXmediated induction of C/EBPd in p53 À/À ;mdm2 À/À MEFs (Supplementary Figure 6) . In further support of normal Rhokinase activity in the absence of Mdm2, we observed no differences in serine 133 phosphorylation of CREB in p53 Although CREB phosphorylation was comparable in MEFs of both genotypes, the induction of several cAMP-responsive CREB target genes 8, 30 was perturbed in p53 À/À ;mdm2
MEFs upon IBMX treatment (Figure 4a ). We therefore speculated whether Mdm2 could be a direct modulator of CREB activity. We measured the transcriptional activity of CREB fused to the GAL4 DNA-binding domain in the absence and presence of increasing levels of Mdm2 in p53 À/À ;mdm2
MEFs. As shown in Figure 4b , Mdm2 enhanced the activity of the fusion protein markedly in the presence of forskolin. CREB is not only activated by elevated cAMP levels, but also by several growth factors, hormones and by stress signals. A commonly used stress activator of CREB is the phorbol ester TPA/PMA (phorbol 12-myristate 13-acetate). cAMP and TPA elicit two distinct transcriptional programs through CREB. 9 To examine if the requirement for Mdm2 in CREB-dependent transactivation was restricted to cAMPmediated activation, we treated p53 À/À and p53 À/À ;mdm2
MEFs with vehicle or TPA. As shown in Figure 4c , TPA administration failed to induce the expression of examined CREB target genes in p53 À/À ;mdm2 À/À MEFs. Collectively, these data suggest that Mdm2 is required for the activation of CREB in response to both stress and cAMP-elevating stimuli.
Mdm2 is required for recruitment of Crtc2/TORC2 to the c/ebpd promoter. A family of transcriptional cofactors, denoted as CREB-regulated transcription coactivator (Crtcs or TORCs), has recently been implicated in the cAMP-mediated response of CREB. The Crtcs solely coactivate CREB bound to genes regulated by cAMP 9 by facilitating the recruitment of the two histone acetylases p300 and CBP to CREB. 8, 9 Under basal conditions, Crtc is localized to the cytoplasm as a result of a phosphorylation-dependent interaction with 14-3-3 proteins, mediated by members of the salt-inducible kinase (SIK) family. Upon elevated cAMP levels, PKA inhibits the SIKs, leading to dephosphorylation and translocation of Crtc to the nucleus and subsequent coactivation of CREB. ;mdm2 À/À MEFs were induced to undergo adipogenesis according to the MDI standard protocol in the presence of rosiglitazone. mRNA levels of Krox20, C/EBPs, PPARg, XOR and KLF5 were assessed using real-time PCR. (c) Wild-type MEFs were treated with Dex, IBMX, insulin or rosiglitazone. Expression of C/EBPd was scored 24 h later using real-time PCR. (d) Wild-type MEFs were treated for 24 h with vehicle, PKA activator, Epac activator or both. mRNA levels of C/EBPd were measured using real-time PCR. (e) P53 À/À and p53 À/À ;mdm2 À/À MEFs were treated with either vehicle, IBMX or forskolin for 1 h. Expression of C/EBPd was assessed using real-time PCR mRNA level. Although there is no specific chemical inhibitor of SIK, the general kinase inhibitor staurosporine has been used as it inhibits SIK at low concentrations. 32 We show that while staurosporine induced C/EBPd expression in p53 À/À MEFs, it did not change the level of C/EBPd mRNA in p53 Of the three Crtcs, Crtc2 is the best described and has been reported to be expressed in adipose tissue. 33 We therefore examined if Mdm2 could interact directly with Crtc2. Using GST pull down, we were able to pull down in vitro translated Crtc2 with GST-Mdm2, but not with GST alone (Figure 5d ). Interestingly, Crtc2 was able to interact separately with the two halves of Mdm2 albeit with lower affinity than full-length Mdm2 (Figure 5d ).
The N-terminal half of Mdm2 harbor the nuclear localization and export signals. As the Crtcs are imported into the nucleus upon cAMP stimulation, we speculated if Mdm2 was required for this translocation. However, GFP-tagged Crtc2 localized to the nucleus upon cAMP stimulation in both p53 Figure 9) . Both elements deviate from the consensus at only one position. We found no putative CREs within or 5 kb downstream of the murine c/ebpd gene. In contrast to mice, humans have four putative CREs within the 5 kb region upstream of the transcriptional start site.
Using chromatin immunoprecipitation (ChIP), we assessed differences in the recruitment of the active CREB transcriptional complex in response to increased cAMP levels. Phosphorylated CREB was recruited to the proximal CRE (CRE2) relative to the transcriptional start site in the c/ebpd promoter upon IBMX treatment (Figure 5e ). Interestingly, Mdm2 was required for the recruitment of Crtc2 to the same CRE. The inability to form a transcriptional active complex on the c/ebpd promoter in the absence of Mdm2 was underscored by the finding that in contrast to p53 À/À MEFs, binding of the two histone acetylases p300 and CBP was not increased in p53
À/À MEFs upon IBMX treatment. Western blotting showed equal levels of P-CREB, Crtc2, p300 and CBP in p53 À/À and p53 Figure 10) . Collectively, these data indicate that Mdm2 is required for CREB-mediated induction of C/EBPd by facilitating the assembly of the transcriptional complex consisting of CREB, Crtc2 and p300/CBP on the c/ebpd promoter. ;mdm2 À/À MEFs were treated with TPA for 1 h. mRNA levels were measured using real-time PCR Mdm2 regulates CREB activity during adipogenesis P Hallenborg et al
MEFs (Supplementary

Discussion
The transcription factor CREB plays a key role in adipocyte differentiation. [4] [5] [6] Our results show that Mdm2 enhances CREB activity and adipocyte differentiation by facilitating the recruitment of Crtc2 and p300/CBP to CREB bound to the c/ebpd promoter. Conversely, MEFs lacking mdm2 fail to undergo adipocyte differentiation.
Our ex vivo data revealed a striking dependency on Mdm2 for adipocyte differentiation by facilitating the induction of C/EBPd. However, CT scans of mice harboring and lacking Mdm2 revealed no statistically significant difference in total adipose tissue (P ¼ 0.08). In their analyses of mice lacking C/EBPd, C/EBPb or both, Akira and co-workers 2 did not observe a decreased weight of adipose tissue in mice lacking either C/EBPd or C/EBPb. Only mice lacking both C/EBPs had a significant decrease in adipose mass. It is therefore conceivable that C/EBPd is dispensable for adipogenesis in mice lacking Mdm2, and that C/EBPb, the expression of which is unaffected by the absence of Mdm2, is sufficient to support adipogenesis in vivo.
Given the importance of Crtc2 in regulating a distinct transcriptional program through CREB downstream of cAMP stimulation, the modes of regulating the activity of the cofactor have been an area of intense research.
In resting cells, Crtc2 is localized to the cytoplasm. Upon cAMP stimulation Crtc2 translocates to the nucleus. 7 We observed no difference in the ability to translocate exogenously expressed Crtc2 in p53 À/À and p53
À/À
;mdm2 À/À MEFs upon cAMP elevation, arguing for normal translocation of Crtc2 in the absence of Mdm2.
Activation of Crtc2 is controlled by several serine phosphorylations, all exerting an inhibitory function on Crtc2 by either decreasing its coactivator activity or ablating nuclear translocation. 35 These phosphorylations can all be removed by treating cells with the general kinase inhibitor, staurosporine. 35 Intriguingly, although staurosporine was able to induce C/EBPd expression in p53 À/À , the inhibitor was unable to induce C/EBPd expression in p53 À/À ;mdm2
MEFs. This demonstrates that even removal of inhibitory phosphorylations on Crtc2 was unable to restore C/EBPd induction in p53 Figures 10 and 11) , demonstrating that deficient IBMX-mediated dephosphorylation was not the cause of abated Crtc2 activation upon cAMP stimulation in mdm2-deficient MEFs.
As Mdm2 is an ubiquitin ligase and regulates the stability of, for example, p53, it is of interest that the stability of Crtc2 has been reported to be regulated by ubiquitination. 36 However, ;mdm2 À/À MEFs were left untreated or stimulated with IBMX for 30 min. Binding of P-CREB, Crtc2, p300 and CBP to the c/ebpd promoter was assessed by chromatin immunoprecipitation. Non-specific IgG was included as control. b-Globin was used to assess background levels both the level and stability of Crtc2 were similar in p53 À/À and p53
À/À MEFs (Supplementary Figure 11) . Interestingly, the activity of Crtc2 is augmented by a p300-mediated acetylation. 36 Given our demonstration that Mdm2 can directly interact with Crtc2, and previous evidence that it can also interact with p300/CBP, 37 it is possible that Mdm2 serves as a scaffold for the interaction between p300/CBP and Crtc2 and thereby facilitates the acetylation and activation of the latter. Although both the C-and the N-terminal halves of Mdm2 can interact with Crtc2, the ability of the N-terminal part of Mdm2 to restore adipogenesis might reflect the potential of this half of Mdm2 to also bind p300/CBP. 37 Besides the involvement of Mdm2 in the cAMP-stimulated activation of CREB, Mdm2 is also required for in stressmediated stimulation of CREB. This was shown by the impaired induction of CREB-responsive genes in cells lacking Mdm2 after TPA treatment. As TPA-mediated activation of CREB is independent of Crtc2 recruitment, it is most likely that Mdm2 regulates CREB downstream of stress signals through a distinct mechanism.
Our data point to a p53-independent requirement of Mdm2 for adipocyte differentiation. Given the important role of Mdm2 in regulating p53 activity and the recently shown inhibitory effect of p53 on adipogenesis, 38 it is conceivable that Mdm2 exerts dual functions in relation to the regulation of adipocyte differentiation. Mdm2 could theoretically augment adipogenesis through potentiating of CREB-mediated transactivation and restriction of p53 activity. Further studies are required to determine the relative contribution of Mdm2 to these two functions. This could be assessed by comparing adipogenesis in wild-type and p53-deficient MEFs deficient for Mdm2 through Cre-mediated deletion of floxed-Mdm2 alleles or lowered expression through siRNA-mediated knockdown of Mdm2.
Earlier studies have shown that increased levels of Mdm2 block myocyte differentiation due to inhibition of Sp1 activity. 21, 22 Here, we show that Mdm2 favors the differentiation of adipocytes at the expense of myogenesis. As myocytes and adipocytes originate from MSCs, it is possible that Mdm2 is involved in the determination of cell fate of MSCs, a notion underscored by the consistent amplification of Mdm2 in liposarcomas.
Materials and Methods
Cell culture and differentiation. Wild-type MEFs were a generous gift from Dr. Jiri Bartek. P53 À/À and p53
;mdm2 À/À MEFs have been described previously. 39 MEFs were grown in AmnioMax basal medium (Invitrogen, Carlsbad, CA, USA) supplemented with 7.5% fetal bovine serum, 7.5% AmnioMax-C100 supplement (Invitrogen), 2 mM glutamine, 62.5 mg/ml penicillin and 100 mg/ml streptomycin (Lonza, Basel, Switzerland). The medium was changed every second day. For differentiation, 2-day postconfluent cells (day 0) were treated with growth medium containing 1 mM Dex (Cat. no. D1756), 0.5 mM IBMX (Cat. no. I7018), 1 mg/ml Ins (Cat. no. I6634) (all Sigma-Aldrich, St. Louis, MO, USA). From days 2 to 4, the medium contained Ins. Rosiglitazone (0.5 mM) (Cat no. 71740; Cayman, Ann Arbor, MI, USA) or vehicle (DMSO) (Cat no. D8418; Sigma-Aldrich) was added throughout differentiation. Forskolin (10 mM) (Cat. no. F3917) and TPA/PMA (20 nM) (Cat. no. P1585) were from Sigma-Aldrich; staurosporine (10 nM) (Cat. no. S-9300) from LC Laboratories (Woburn, MA, USA); Rho kinase inhibitor (10 mM) (Cat. no. 555550) from Calbiochem (San Diego, CA, USA); and specific PKA (100 mM) (Cat. no. M 003) and Epac (200 mM) (Cat. no. C 041) activators were from Biolog (Hayward, CA, USA). Cycloheximide (Cat. no. O1810; Sigma-Aldrich) was used in a concentration of 15 mg/ml. Retroviral transduction. Phoenix cells were transfected with pBABE-based plasmids. At 2 days post-transfection, media were isolated, spun down at 1200 Â g for 5 min to remove cellular debris, mixed 1 : 1 with standard media and added to cells. Polybrene was added to a final concentration of 6 mg/ml. Cells were selected for 2 days using puromycin (3 mg/ml).
Chromatin immunoprecipitation. ChIP was carried out essentially as described previously, 40 except that crosslinking was carried out by adding formaldehyde directly to the media to a final concentration of 1%, followed by incubation at 371C for 20 min. Furthermore, 48 rounds of sonication were applied. Finally, DNA was purified by phenol-chloroform extraction. Antibodies used were P-CREB-1 (Ser133) (sc-7978), CBP (sc-369), p300 (sc-584) and Crtc2 (sc-46272) (all from Santa Cruz Technology, Santa Cruz, CA, USA). Primer sequences are CRE1, RNA purification, reverse transcription and real-time PCR. RNA was purified using TRIzol (Invitrogen) according to the manufacturer's instructions.
Reverse transcription was performed essentially as described elsewhere. 41 Quantitative PCR was performed in 20 ml reactions containing SYBR À Green JumpStart Taq ReadyMix (Sigma-Aldrich), 1.5 ml of diluted cDNA and 300 nM of each primer. Reaction mixtures were preheated at 941C for 2 min, followed by 40 cycles of melting at 941C for 15 s, annealing at 601C for 30 s and elongation at 721C for 45 s. Reactions were ran on a Stratagene MX3000P and quantified using Stratagene MxPro. Primer sequences are included in supporting Materials and Methods.
